Zymeworks Inc. (ZYME) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-07-06

Zymeworks Inc. (ZYME) has filed 2 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-06. 3 Form 8-K material event filings were reported by ZYME in the last 90 days. InsiderAlpha tracks every ZYME SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Zymeworks Inc. (ZYME)

SEC CIK	0001937653

90-Day SEC Filing Activity

Form 4 filings (90d)	2
Form 8-K filings (90d)	3
Latest Form 4 filing	2026-07-06

Recent ZYME Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-07-06	Hollywood Mark	EVP & Chief Operating Officer	A — Grant or award	939	$22.22	$21K	SEC
2026-01-12	Hollywood Mark	EVP & Chief Operating Officer	S — Open-market sale	6.1K	$22.67	$139K	SEC
2026-01-12	Moore Paul Andrew	Chief Scientific Officer	S — Open-market sale	9.6K	$22.67	$217K	SEC
2026-01-12	Hollywood Mark	EVP & Chief Operating Officer	M — Option exercise	17.7K	$0.00	—	SEC
2026-01-12	Smith Jeffrey T L	EVP & Chief Medical Officer	S — Open-market sale	9.3K	$22.67	$211K	SEC
2026-01-12	Moore Paul Andrew	Chief Scientific Officer	M — Option exercise	17.7K	$0.00	—	SEC
2026-01-12	Smith Jeffrey T L	EVP & Chief Medical Officer	M — Option exercise	17.7K	$0.00	—	SEC
2026-01-12	Galbraith Kenneth	Chair & CEO	M — Option exercise	64.0K	$0.00	—	SEC
2026-01-12	Galbraith Kenneth	Chair & CEO	S — Open-market sale	30.4K	$22.67	$690K	SEC
2026-01-06	PATTERSON LEONE D	EVP, Chief Bus & Fin Officer	A — Grant or award	459	$10.55	$5K	SEC
2026-01-05	Moore Paul Andrew	Chief Scientific Officer	S — Open-market sale	10.8K	$25.10	$272K	SEC
2026-01-05	Galbraith Kenneth	Chair & CEO	M — Option exercise	47.7K	$0.00	—	SEC
2026-01-05	Galbraith Kenneth	Chair & CEO	S — Open-market sale	22.7K	$25.10	$569K	SEC
2026-01-05	Galbraith Kenneth	Chair & CEO	M — Option exercise	66.7K	$0.00	—	SEC
2026-01-05	Galbraith Kenneth	Chair & CEO	S — Open-market sale	31.7K	$25.10	$795K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Zymeworks Inc. (ZYME). Updated in real time as new filings are submitted to the SEC.

Most-Active ZYME Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Schneider Paul R	2	—
Hollywood Mark	1	$21K

Recent ZYME Form 8-K Material Events

2026-06-29 — Item 1.01, 7.01, 9.01 [SEC]
2026-05-14 — Item 7.01, 8.01, 9.01 [SEC]
2026-05-07 — Item 2.02, 7.01, 9.01 [SEC]
2026-04-01 — Item 5.02, 9.01 · Leadership · neutral [SEC]
Zymeworks Inc. appointed Kristin Stafford as Executive Vice President and Chief Financial Officer, effective April 1, 2026. Stafford brings significant pharma finance experience from roles at Royalty Pharma, BioPharma Credit, and prior positions at EY and Deloitte, with a CPA cre
2026-03-02 — Item 1.01, 2.03, 7.01, 9.01 · Financing · positive [SEC]
Zymeworks Inc. sold a 30% royalty interest in future Ziihera (zanidatamab-hrii) payments to Royalty Pharma for $250 million. This is a royalty monetization transaction that provides immediate capital to the company while retaining 70% of future royalty upside from the drug's comm

Recent Insider Filings

2026-07-06 — Hollywood Mark (EVP & Chief Operating Officer)
2026-05-15 — Schneider Paul R (EVP, General Counsel)
2026-04-10 — Schayowitz Adam (See Remarks)
2026-04-10 — Platshon Scott (EVP, Chief Business Officer)
2026-04-07 — Stafford Kristin (EVP, Chief Financial Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ZYME insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

ZYME Insider Trading — FAQ

What is the latest insider trade for ZYME?: Zymeworks Inc. (ZYME) had 2 insider filings in the last 90 days, with the most recent on 2026-07-06. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying ZYME stock?: 0 insider purchases of ZYME were filed in the last 90 days.
How many insiders are selling ZYME stock?: 0 insider sales of ZYME were filed in the last 90 days.
Where can I see ZYME SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every ZYME SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live ZYME dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.